[h=3]Post-Marketing Experience[/h]In addition to the adverse reactions reported during clinical trials and listed above, adverse events have also been identified during post-approval use of Xyzal in other countries. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse events of hypersensitivity and anaphylaxis, angioedema, fixed drug eruption, pruritus, rash, and urticaria, convulsion, paraesthesia, dizziness, aggression and agitation, hallucinations, depression, visual disturbances, blurred vision, palpitations, tachycardia, dyspnea, nausea, vomiting, hepatitis, dysuria, and myalgia have been reported.